ClinicalTrials.gg
CompletedNCT06547164Updated Sep 4, 2025

A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

A Phase 1 interventional study of Midazolam and Camizestrant in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to female participants aged 50 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
50 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing AZD9833 in Breast Neoplasms — 6 open to participants now, 10 under way, 7 of them phase 3. AZD9833 · Breast Neoplasms.

Enrollment
12th of 17
40 · median 150
Started
2024
with 1 other
Phase 1
7 of 17
none open now
Registered
13th of 17
by date
Lead sponsor
15 of 17
AstraZeneca

Among the 17 studies testing AZD9833 in Breast Neoplasms, this one is the 12th largest by enrollment, is one of 2 that started in 2024, is one of 7 in phase 1, and was the 13th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 17 studies testing AZD9833 in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About AZD9833

AZD9833: first FDA approval 2026 (ETCAMAH), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 50 Years to 70 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing AZD9833 in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will be conducted in order to determine the effect of repeated oral doses of camizestrant on the pharmacokinetics (PK) of midazolam and to determine the effect of repeated oral titrated doses of carbamazepine on the PK of camizestrant in healthy post-menopausal female participants.

Read the detailed description

This is an open-label, fixed sequence, 2-part (Part A and Part B), drug-drug interaction study in healthy post-menopausal female participants. Participants enrolled in Part A may subsequently also participate in Part B.

Part A of the study will assess the effect of repeated oral doses of camizestrant on the PK of a single oral dose of midazolam. It will comprise:

  • A Screening Period of maximum 28 days.
  • Three Treatment Periods during which participants will be resident at the Clinical Unit from the day before study intervention administration (Day -1) until after the last camizestrant PK sample on Day 8.

    1. Period 1: participants will receive a single oral dose of midazolam (Day 1).
    2. Period 2: participants will receive an oral once daily (OD) dose of camizestrant (Day 2 to Day 6).
    3. Period 3: participants will receive a single oral dose of midazolam and camizestrant (Day 7).
  • A Follow-up Visit, for which the participant will return to the Clinical Unit 7 (± 2) days after the last camizestrant PK sample in Period 3.

Part B of the study will assess the effect of multiple oral doses of carbamazepine on the PK of a single oral dose of camizestrant. It will comprise:

  • A Screening Period of maximum 28 days.
  • Two Treatment Periods during which participants will be resident at the Clinical Unit from the day before study intervention administration (Day -1) until after the last camizestrant PK sample on Day 16.

    1. Period 1: participants will receive a single oral dose of camizestrant (Day 1) with PK sampling on Day 1 to Day 4.
    2. Period 2: participants will receive low oral doses (Dose 1) of carbamazepine twice a day (BID) on Day 4 to Day 6, mid oral doses (Dose 2) of carbamazepine BID on Day 7 to Day 9, and high oral doses (Dose 3) of carbamazepine BID on Day 10 to Day 15. On Day 13, participants will receive a single oral dose of camizestrant.
  • A Follow-up Visit, for which the participant will return to the Clinical Unit 7 (± 2) days after the last camizestrant PK sample in Period 2.
03

Conditions studied

  • Healthy Participants

Browse trials for

Keywords

  • Midazolam
  • Camizestrant
  • Carbamazepine
  • Post-menopausal
  • Estrogen receptor (ER) positive disease
  • Breast Cancer
  • Cytochrome P450, family 3, subfamily A (CYP3A)
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy female participants with suitable veins for cannulation or repeated venipuncture.
  • Female participants must be post-menopausal as confirmed at the Screening Visit. Post-menopausal defined as amenorrhoea for at least 12 months or more without an alternative medical or surgical cause and confirmed by a follicle stimulating hormone (FSH) result of ≥ 30 Internation units/liter (IU/L).
  • Have a between 19 and 35 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
  • Must agree to not use warfarin or phenytoin (and other coumarin-derived vitamin K antagonist anticoagulants) during the study, and for 2 weeks after last administration of study intervention.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder.
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • History of any clinically significant cardiovascular, chronic respiratory disease, haematological, neurological or psychiatric disorder.
  • History of acute pulmonary insufficiency marked neuromuscular respiratory weakness, obsessional states, phobic states, sleep apnoea syndrome, and unstable myasthenia gravis.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
  • Any clinically important abnormalities in clinical chemistry, haematology, or urinalysis results.
  • Any relevant history or known risk factors of or have received drugs known to prolong QT interval.
  • Any positive result for serum surface antigen (HBsAg), virus (HCV) antibody or (HIV).
  • History of or ongoing clinically important allergy/, or history of hypersensitivity to drugs with a similar chemical structure or class to camizestrant or the formulation .
  • Presence of any to the probe substrate carbamazepine.
  • Presence of any contraindication to midazolam.
  • Have any active indication for therapeutic anticoagulation, and/or having taken an anticoagulant within 14 days of Screening Visit.
  • Part B only: Participants identified to carry human leukocyte antigen (HLA)-A*3101 and/or HLA-B*1502 allele.
  • Participants with bone marrow suppression or a history of bone marrow suppression or aplastic anaemia.
  • History of or ongoing clinically significant visual disturbances including but not limited to visual hallucinations, migraine with visual symptoms, blurred vision, frequent floaters/flashes associated with other symptoms such as dizziness.
  • Participants with family history of glaucoma or closed angle glaucoma or participants who are currently on anticholinergic medications.
  • Participants with an anticipated need for major surgery and/or any surgery requiring general anaesthesia during the participation in the study.
  • Vulnerable participants, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Part A: Midazolam + Camizestrant

    Participants will receive a single oral dose of midazolam on Day 1 in Period 1, followed by oral dose of camizestrant OD from Day 2 to Day 6 in Period 2, and then single oral dose of midazolam with camizestrant on Day 7 with PK sampling on Day 7 to Day 8 in Period 3.

    Drug: Midazolam · Drug: Camizestrant

  • Experimental
    Part B: Camizestrant + Carbamazepine

    Participants will receive a single oral dose of camizestrant on Day 1 with PK sampling on Day 1 to Day 4 in Period 1, followed by low oral doses of carbamazepine BID on Day 4 to Day 6, mid oral doses of carbamazepine BID on Day 7 to Day 9 and high oral doses of carbamazepine BID on Day 10 to Day 15 with single oral dose of camizestrant on Day 13 with PK sampling on Day 16 in Period 2.

    Drug: Camizestrant · Drug: Carbamazepine

Interventions

  • Midazolam will be administered orally.

  • Camizestrant will be administered orally.

    Also known as: AZD9833

  • Carbamazepine will be administered orally.

06

What researchers measure

Primary outcomes

  1. Part A: Area under concentration-time curve from time 0 to infinity (AUCinf) of midazolam

    To determine the effect of repeated oral doses of camizestrant on the key PK parameters of a single oral dose of midazolam in healthy postmenopausal female participants.

    Time frame: Period 1 (Day 1) and Period 3 (Day 7 to Day 8)

  2. Part A: Area under concentrationcurve from time 0 to the last quantifiable concentration (AUClast) of midazolam

    To determine the effect of repeated oral doses of camizestrant on the key PK parameters of a single oral dose of midazolam in healthy postmenopausal female participants.

    Time frame: Period 1 (Day 1) and Period 3 (Day 7 to Day 8)

  3. Part A: Maximum observed plasma (peak) drug concentration (Cmax) of midazolam

    To determine the effect of repeated oral doses of camizestrant on the key PK parameters of a single oral dose of midazolam in healthy postmenopausal female participants.

    Time frame: Period 1 (Day 1) and Period 3 (Day 7 to Day 8)

  4. Part B: Area under concentration-time curve from time 0 to infinity (AUCinf) of camizestrant

    To determine the effect of repeated oral titrated doses of carbamazepine on the PK of a single oral dose of camizestrant in healthy postmenopausal female participants.

    Time frame: Period 1 (Day 1 to Day 4), Period 2 (Day 22 to Day 25)

  5. Part B: Area under concentrationcurve from time 0 to the last quantifiable concentration (AUClast) of camizestrant

    To determine the effect of repeated oral titrated doses of carbamazepine on the PK of a single oral dose of camizestrant in healthy postmenopausal female participants.

    Time frame: Period 1 (Day 1 to Day 4), Period 2 (Day 22 to Day 25)

  6. Part B: Maximum observed plasma (peak) drug concentration (Cmax) of camizestrant

    To determine the effect of repeated oral titrated doses of carbamazepine on the PK of a single oral dose of camizestrant in healthy postmenopausal female participants.

    Time frame: Period 1 (Day 1 to Day 4), Period 2 (Day 22 to Day 25)

Secondary outcomes

  1. Part A: Time to reach maximum observed concentration (tmax) of midazolam

    To further characterise the effect of camizestrant on the PK of midazolam, and the effect of carbamazepine on the PK of camizestrant, in healthy post-menopausal female participants.

    Time frame: Period 1 (Day 1) and Period 3 (Day 7 to Day 8)

  2. Part A: Terminal elimination half-life (t½λz) of midazolam

    To further characterise the effect of camizestrant on the PK of midazolam, and the effect of carbamazepine on the PK of camizestrant, in healthy post-menopausal female participants.

    Time frame: Period 1 (Day 1) and Period 3 (Day 7 to Day 8)

  3. Part A: Terminal rate constant (λz) of midazolam

    To further characterise the effect of camizestrant on the PK of midazolam, and the effect of carbamazepine on the PK of camizestrant, in healthy post-menopausal female participants.

    Time frame: Period 1 (Day 1) and Period 3 (Day 7 to Day 8)

  4. Part A: Apparent total body clearance (CL/F) of midazolam

    To further characterise the effect of camizestrant on the PK of midazolam, and the effect of carbamazepine on the PK of camizestrant, in healthy post-menopausal female participants.

    Time frame: Period 1 (Day 1) and Period 3 (Day 7 to Day 8)

  5. Part A: Apparent volume of distribution based on the terminal phase (Vz/F) of midazolam

    To further characterise the effect of camizestrant on the PK of midazolam, and the effect of carbamazepine on the PK of camizestrant, in healthy post-menopausal female participants.

    Time frame: Period 1 (Day 1) and Period 3 (Day 7 to Day 8)

  6. Part A: Plasma concentration of camizestrant

    To further characterise the effect of camizestrant on the PK of midazolam, and the effect of carbamazepine on the PK of camizestrant, in healthy post-menopausal female participants.

    Time frame: Period 3: Pre-dose and 3 hours post-dose of Day 7 and Day 8

  7. Part B: Time to reach maximum observed concentration (tmax) of camizestrant

    To further characterise the effect of camizestrant on the PK of midazolam, and the effect of carbamazepine on the PK of camizestrant, in healthy post-menopausal female participants.

    Time frame: Period 1 (Day 1 to Day 4), Period 2 (Day 22 to Day 25)

  8. Part B: Terminal elimination half-life (t½λz) of camizestrant

    To further characterise the effect of camizestrant on the PK of midazolam, and the effect of carbamazepine on the PK of camizestrant, in healthy post-menopausal female participants.

    Time frame: Period 1 (Day 1 to Day 4), Period 2 (Day 22 to Day 25)

  9. Part B: Terminal rate constant (λz) of camizestrant

    To further characterise the effect of camizestrant on the PK of midazolam, and the effect of carbamazepine on the PK of camizestrant, in healthy post-menopausal female participants.

    Time frame: Period 1 (Day 1 to Day 4), Period 2 (Day 22 to Day 25)

  10. Part B: Apparent total body clearance (CL/F) of camizestrant

    To further characterise the effect of camizestrant on the PK of midazolam, and the effect of carbamazepine on the PK of camizestrant, in healthy post-menopausal female participants.

    Time frame: Period 1 (Day 1 to Day 4), Period 2 (Day 22 to Day 25)

  11. Part B: Apparent volume of distribution based on the terminal phase (Vz/F) of camizestrant

    To further characterise the effect of camizestrant on the PK of midazolam, and the effect of carbamazepine on the PK of camizestrant, in healthy post-menopausal female participants.

    Time frame: Period 1 (Day 1 to Day 4), Period 2 (Day 22 to Day 25)

  12. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    To evaluate the safety and tolerability of camizestrant, alone and in combination with midazolam and carbamazepine, respectively, in healthy post-menopausal female participants.

    Time frame: For SAEs - Part A: From screening (Day -28 to Day -2) to 7 weeks; Part B: From screening (Day -28 to Day -2) to 9 weeks. For AEs: Part A: From Day 1 to 7 weeks; Part B: From Day 1 to 9 weeks

07

Study locations

1 site
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Aug 2025, 11 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 11 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2024
First posted
Aug 9, 2024
StartActual
Aug 27, 2024
Primary completionActual
Aug 20, 2025
CompletionActual
Aug 20, 2025
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06547164
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Aug 27, 2024
Primary completion
Aug 20, 2025
Completion
Aug 20, 2025
Last update
Sep 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD9833

Start the discussion